Pharma & Biotech News , from our Global Correspondents
Refine Search
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Pharmaceutical
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
Generics
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
Pharmaceutical
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
Biotechnology
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
Generics
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
Generics
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Pharmaceutical
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Pharmaceutical
Russia is sharply cutting centralized state purchases of anti-HIV drugs due to the problems with funding and the reduction of supplies to Russia by global drugmakers, reports The Pharma Letter’s local correspondent. 12 June 2024
Generics
Indian generics drugmaker Cadila Pharmaceuticals, together with the Russian investment fund the Russian Direct Investment Fund (RDIF), will invest more than 10 billion roubles ($112 million) in the establishment of a pharmaceutical complex and an injection drug plant in Russia. 11 June 2024
Pharmaceutical
Russian drugmaker Nanolek plans to accelerate its expansion this year by expanding its range and increase of output, paying a particular focus to vaccines, The Pharma Letter’s local correspondent reports. 5 June 2024
Generics
India has become the largest supplier of drugs to the Russian market, overtaking Germany, which had been in the lead for the last two years, reports The Pharma Letter’s Russia correspondent. 4 June 2024
Pharmaceutical
Russia has suspended state purchases of a number of original anti-cancer drugs due to problems associated with sanctions and the ever-growing isolation of the country in the international arena, The Pharma Letter’s local correspondent reports. 29 May 2024
Generics
The drug shortage crisis in the USA, intensified by supply chain disruptions and increased demand, presents a significant opportunity for Indian pharmaceutical companies to offer essential support. 28 May 2024
Pharmaceutical
Russia has registered a new domestic drug, fluorothiazinone, which is intended for the treatment of bacterial infections caused by microorganisms resistant to antibiotics, reports The Pharma Letter’s local correspondent. 28 May 2024
Generics
The Russian government is considering tightening domestic patent legislation, in a move to respond to numerous calls of global drugmakers, which are unhappy with the level of protection of their original drugs in the local market, reports The Pharma Letter’s local correspondent. 22 May 2024
Biotechnology
Given that the USA’s House Committee on Oversight and Accountability held a markup meeting last week on the legislation, it is likely that the USA will pass the BIOSECURE Act (the Act) in December this year. 21 May 2024
Biosimilars
As the Indian pharmaceutical industry is propelled by government initiatives to transition from its traditional focus on generic drug production to the development of high-value, innovative products, domestic pharma majors are advocating for a robust US-India trade partnership. 20 May 2024
Pharmaceutical
Russia has faced with the shortage of oncology drug Uromitexan (mercapto ethane sulphonacid; mesna), for which last deliveries to the country were in the spring of 2023, reports The Pharma Letter’s local correspondent. 15 May 2024
Generics
The Russian Ministry of Health has registered domestic generic of Spinraza (nusinersen), an expensive drug used for the treatment of all types of spinal muscular atrophy (SMA) in children and adults, reports The Pharma Letter’s local correspondent. 14 May 2024
Pharmaceutical
Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by involuntary movements, cognitive decline, and emotional disturbances.1 Recent global prevalence data cites 4.88 per 100,000 persons and an incidence of 0.48 cases per 100,000 person-years.2 13 May 2024
Pharmaceutical
As artificial intelligence (AI) and machine learning (ML) continue to revolutionize various industries, the pharmaceutical sector is no exception. Indeed, there has been a substantial surge in drug and biologic submissions incorporating AI/ML components, exceeding 100 submissions in 2021 alone.1 10 May 2024
Pharmaceutical
The US drugmaker Baxter (NYSE: BAX), one of the largest suppliers of dialysis solutions, has suspended its commercial activities in Russia. 8 May 2024
Generics
The level of competition in the Russian market of anti-HIV drugs is tightening, due to the plans of global drugmakers to launch their products and expand their existing portfolios, The Pharma Letter’s local correspondent reports. 1 May 2024
Pharmaceutical
A full cycle of production of a drug for the treatment of Fabry disease will be launched in Russia this year, reports The Pharma Letter’s local correspondent. 30 April 2024
Biosimilars
As over 20 drugs with a combined annual sales value of $250 billion are set to go off-patent, Indian companies have been exhorted to step in with generic and biosimilar versions. 30 April 2024
Generics
UK pharma major AstraZeneca has appealed to the Russian Investigative Committee and the Federal Anti-Monopoly Service (FAS) against Russian drug firm Akrikhin, which produces a generic of the diabetes drug Forxiga (dapagliflozin) during the validity of the patent. 24 April 2024
Generics
Global drugmakers are losing their market share in the Russian market for erectile dysfunction drug, which is rapidly being taken over by local players, reports The Pharma Letter’s local correspondent. 23 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze